Zhao, Jianping

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet

COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 48,884

Clinical and immunological features of severe and moderate coronavirus disease 2019

Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation

COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 4,750

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Chen, T., Wu, D., Chen, H., Yan, W., Yang, D., Chen, G., Ma, K., Xu, D., Yu, H., Wang, H., et al. (2020) · BMJ

COVID-19 Clinical Research StudiesLong-Term Effects of COVID-19

Cited by 3,903

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial

Cao, Y., Wei, J., Zou, L., Jiang, T., Wang, G., Chen, L., Huang, L., Meng, F., Huang, L., Wang, N., et al. (2020) · Journal of Allergy and Clinical Immunology

COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 456

MBD2 serves as a viable target against pulmonary fibrosis by inhibiting macrophage M2 program

Wang, Y., Zhang, L., Wu, G.-R., Zhou, Q., Yue, H., Rao, L.-Z., Yuan, T., Mo, B., Wang, F.-X., Chen, L.-M., et al. (2021) · Science Advances

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related Diseases

Cited by 227

IL-24 deficiency protects mice against bleomycin-induced pulmonary fibrosis by repressing IL-4-induced M2 program in macrophages

Rao, L.-Z., Wang, Y., Zhang, L., Wu, G., Zhang, L., Wang, F.-X., Chen, L.-M., Sun, F., Jia, S., Zhang, S., et al. (2021) · Cell Death & Differentiation

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisTransplantation: Methods and Outcomes

Cited by 153